1621482-75-4

Upstream product

• 15260-10-3 N-Boc-O-benzyl-L-threonine 
• 1621482-73-2 tert-buty 2-(((2S,3R)-3-(benzyloxy)-1-oxo-1-(pyrrolidin-1-yl)butan-2-yl)carbamoyl)-2-(1-hydroxyethyl)-5-methylpyrrolidine-1-carboxylate 
• 1621435-51-5 (2S,3R)-2-amino-3-(benzyloxy)-1-(pyrrolidin-1-yl)butan-1-one 
• 1621435-50-4 tert-butyl ((2S,3R)-3-(benzyloxy)-1-oxo-1-(pyrrolidin-1-yl)butan-2-yl)carbamate 
• 1621435-49-1 1-(tert-butoxycarbonyl)-2-(1-hydroxyethyl)-5-methylpyrrolidine-2-carboxylic acid 
• 1621435-48-0 1-tert-butyl 2-ethyl 2-(1-hydroxyethyl)-5-methylpyrrolidine-1,2-dicarboxylate 
• 2764-43-4 ethyl 5-methylpyrrolidine-2-carboxylate 
• 100911-28-2 5-methyl-3,4-dihydro-2H-pyrrole-2-carboxylic acid ethyl ester 
• 251924-83-1 1-tert-butyl 2-ethyl 5-oxopyrrolidine-1,2-dicarboxylate 
• 66183-71-9 ethyl 2-oxopyrrolidine-5-carboxylate 
• 149-87-1 Pyroglutamic acid 

Relevant academic research and scientific papers

SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF

Disclosed are compounds having enhanced potency in the modulation of NMD A receptor activity. Such compounds are contemplated for use in the treatment of conditions such as depression and related disorders. Orally available formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.